Vendor Intelligence Report: PeptiLab Research

Published 13 Jun 2026. 24-page investigative report on who is behind PeptiLab Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

PeptiLab Research is a product-by-product decision, not a simple safe/unsafe call. Across 15 Finnrick lab tests, PeptiLab records 10 pass / 5 fail, an overall pass rate of 67%. GHK-Cu and Ipamorelin are the relatively stronger tested choices, CJC-1295 is the clear lab-based avoid, and BPC-157 remains mixed. Ratings also compress under stricter grading.

The larger near-term issue is whether an order should be placed at all. June field captures show the US storefront announcing the conclusion of USA operations while a 40% sitewide discount remained active. That matches a prior Australian exit pattern in buyer reports: stalled tracking, silent support, and refund friction. UK non-delivery reports and bank-transfer complaints add payment-protection risk.

PeptiLab’s identity record is less domestic than its Colorado and USA-made presentation. UK filings, footer evidence, and an early hosting artifact point to a UK-controlled operating company behind the US-facing storefront; the file found no verified US manufacturing facility. Archived PeptideWorldwide pages and PeptiLab product copy support a successor-brand finding, while a newer PeptiLab-named UK company remains only a watch item.

For GLP-1 buyers, Finnrick separates lab evidence from complaint and regulatory evidence. Retatrutide is not in the tested PeptiLab set, but UK reviews include allegations of discoloration, clumping, non-response, and inefficacy. GLP-1 products also sit within the FDA import-alert and research-peptide warning-letter fact pattern, adding seizure and continuity risk that does not apply equally to every peptide.

Inside the full report:

  • Per-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 5 tested products
  • Companies House filings, officer/PSC records, and the hosting artifact used to map the operating-control trail
  • PeptideWorldwide-to-PeptiLab lineage analysis using archived pages, copied quality claims, and domain timing
  • US shutdown screenshots, Australian collapse reports, UK non-delivery evidence, and payment-protection analysis
  • Trustpilot removal capture and Retatrutide complaint cluster review
  • COA/source-claim review plus GLP-1 regulatory context from FDA Import Alert 66-80 and the Gram Peptides warning letter

Risk assessment

  • Business-continuity and non-delivery risk — high: US site announced the conclusion of USA operations while running a 40% discount; AU collapse and UK non-delivery reports show the same fulfillment pattern.
  • Product-specific quality risk — high: CJC-1295 failed all 3 Finnrick tests (20.64%); BPC-157 is mixed (49.84%); buyer reports describe Retatrutide discoloration and clumping.
  • GLP-1 regulatory seizure/enforcement risk — high: Semaglutide, Tirzepatide, and Retatrutide sit in the FDA Import Alert 66-80 / Gram Peptides warning-letter fact pattern.
  • Reputation and review-integrity risk — high: Trustpilot removed the US profile for guideline violations; the UK profile was 2.4/5 with 65% one-star reviews in the field capture.
  • Payment-protection risk — medium: Forum buyers reported card logos at checkout but post-order bank-transfer instructions, reducing chargeback protection.
  • Corporate-footprint and source-verification risk — medium: The vendor presents a US-made/Colorado-facing operation, but records identify a UK company, virtual-office footprint, and no verified US manufacturer.